AI Article Synopsis
- Ethical safeguards like debriefing are crucial for research involving deception, but current guidelines on these practices are often unclear and inconsistently applied.
- A study involving interviews with 24 experienced researchers aimed to clarify these safeguards and explore their relationship to truthfulness and ethical decision-making.
- Findings highlighted the variety of reasons for implementing safeguards, which depend on the research context, and pointed out ongoing issues that warrant further exploration and discussion.
Article Abstract
Ethical safeguards such as debriefing are often recommended or required for research studies in which participants are deceived. However, existing guidance on these safeguards seems insufficiently coherent and precise, which may be associated with their suboptimal implementation in practice. This study aimed to contribute to a more coherent and precise framework of ethical safeguards in deceptive studies through semi-structured interviews with a diverse sample of 24 researchers who had significant experience with deception. Interviewees discussed which ethical safeguards they implemented and how, as well as their relation to the notion of truthfulness (i.e., the intentional communication of true information). Moreover, interviewees provided a variety of reasons for and against implementing these safeguards, as well as how these reasons varied with the particular context of a study. Overall, the current study contributes to a more coherent and precise understanding of ethical safeguards in deceptive research that could be useful for guiding researchers and ethics reviewers in their ethical decision-making, although certain imprecisions and incoherent aspects remain in need of further investigation and normative reflection.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1080/08989621.2024.2362777 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Generative AI in Higher Education: Balancing Innovation and Integrity.
Br J Biomed Sci
January 2025
Department of Biosciences and Chemistry, Sheffield Hallam University, Sheffield, United Kingdom.
Generative Artificial Intelligence (GenAI) is rapidly transforming the landscape of higher education, offering novel opportunities for personalised learning and innovative assessment methods. This paper explores the dual-edged nature of GenAI's integration into educational practices, focusing on both its potential to enhance student engagement and learning outcomes and the significant challenges it poses to academic integrity and equity. Through a comprehensive review of current literature, we examine the implications of GenAI on assessment practices, highlighting the need for robust ethical frameworks to guide its use.
View Article and Find Full Text PDFCorrelation between selenium levels and selenoproteins expression in idiopathic generalized epilepsy: a study from Karachi.
BMC Neurol
January 2025
Department of Neurology, Dow University Hospital, Dow University of health sciences, Karachi, Pakistan.
Background: Oxidative damage has been implicated in multiple neurodegenerative diseases, including epilepsy. Selenium, in the form of selenoproteins is an integral part of the human antioxidant defense system. Though a relationship between the altered selenium levels and epilepsy has been reported, limited evidence is available about the expression pattern of selenoproteins in epileptic patients.
View Article and Find Full Text PDFPredictors associated with time to default for HIV/AIDS patients under HAART at Debre Tabor Referral Hospital: a Cox regression model.
Sci Rep
January 2025
Department of Statistics, College of Natural and Computational Science, Debre Tabor University, Debre Tabor, Ethiopia.
The human immunodeficiency virus systematically undermines the immune system, which serves as our body's inherent safeguard against diseases. Currently, it is the most serious threat to public health. Ethiopia is among the countries with the highest prevalence of HIV/AIDS.
View Article and Find Full Text PDFEffect of combination therapy of methylfolate with antidepressants in patients with depressive disorder.
BMC Pharmacol Toxicol
January 2025
Department of Community Medicine, Islamic International Medical College (IIMC), Riphah International University, Rawalpindi, Pakistan.
Objective: To determine the relative effectiveness of combination therapy of antidepressants with low-dose methylfolate versus antidepressant monotherapy in patients with depressive disorder.
Methods: In an open-label clinical trial, forty-four patients with depressive disorder (6A70, 6A71, and 6A72 according to ICD-11) received an evidence-based antidepressant therapy (either escitalopram 10-20 mg, sertraline 50-100 mg, fluoxetine 20-40 mg, duloxetine 30-60 mg, mirtazapine 15-30 mg, venlafaxine 75-150 mg, trazodone 50-100 mg, amitriptyline 25-75 mg, or clomipramine 25-75 mg orally daily for 4 weeks). The experimental group, Group B was additionally given a dose of methylfolate 800 µg daily for four weeks.
Estimating mortality attributable to alcohol or tobacco - a cohort study from Germany.
Subst Abuse Treat Prev Policy
January 2025
Dep Prevention Research and Social Medicine, University Medicine Greifswald, Institute of Community Medicine, W.-Rathenau-Str. 48, 17475, Greifswald, Germany.
Background: Little is known about mortality from four disorder combinations: fully attributable to alcohol or tobacco, partly attributable to both alcohol and tobacco, to tobacco only, to alcohol only.
Aim: To analyze whether residents who had disclosed risky alcohol drinking or daily tobacco smoking had a shorter time to death than non-risky drinkers and never daily smokers twenty years later according to the disorder combinations.
Methods: A random adult general population sample (4,075 study participants) of a northern German area had been interviewed in the years 1996-1997.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!